Patents by Inventor Gregory Haiwick

Gregory Haiwick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190023747
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.
    Type: Application
    Filed: October 8, 2018
    Publication date: January 24, 2019
    Inventors: Luis Alejandro Hernandez, Christine Margaret Muehlenthaler, Eric Martin Vaughn, Gregory Haiwick
  • Patent number: 10131696
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: November 20, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Luis Alejandro Hernandez, Christine Margaret Muehlenthaler, Eric Martin Vaughn, Gregory Haiwick
  • Publication number: 20170232094
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of a different subtype, or the prevention or treatment of a disease caused by an infection with PCV2 of a different subtype.
    Type: Application
    Filed: April 27, 2017
    Publication date: August 17, 2017
    Inventors: Gregory HAIWICK, Marc Allan EICHMEYER, Luis Alejandro HERNANDEZ, Wesley Scott JOHNSON, Christine Margaret MUEHLENTHALER, Eric Martin VAUGHN
  • Patent number: 9561270
    Abstract: The present invention provides methods of reducing the virucidal activity of a composition comprising a PCV-2 antigen as well as antigenic preparations and immunogenic compositions comprising a PCV-2 antigen, wherein the virucidal activity has been reduced. In addition, the present invention also relates to a method of increasing the immunogenicity of an immunogenic composition comprising a PCV-2 antigen as well as immunogenic composition with an increased immunogenicity.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: February 7, 2017
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Caroline Ann Kohler, Guosong Zhao, Ali Khazraeinazmpour, Bernd Colin Eichenmueller, Marc Allan Eichmeyer, Gregory Haiwick, Merrill Lynn Schaeffer
  • Publication number: 20170029471
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.
    Type: Application
    Filed: October 17, 2016
    Publication date: February 2, 2017
    Inventors: Luis Alejandro HERNANDEZ, Christine Margaret MUEHLENTHALER, Eric Martin VAUGHN, Gregory HAIWICK
  • Patent number: 9505808
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: November 29, 2016
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Luis Alejandro Hernandez, Christine Margaret Muehlenthaler, Eric Martin Vaughn, Gregory Haiwick
  • Publication number: 20160206727
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype a (PCV2a) ORF2 proteins or immunogenic compositions comprising a PCV2a ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of a different subtype, or the prevention or treatment of a disease caused by an infection with PCV2 of a different subtype.
    Type: Application
    Filed: April 1, 2016
    Publication date: July 21, 2016
    Inventors: Gregory HAIWICK, Luis HERNANDEZ, Wesley Scott JOHNSON, Christine Margaret MUEHLENTHALER, Eric Martin VAUGHN
  • Publication number: 20150093404
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.
    Type: Application
    Filed: October 2, 2014
    Publication date: April 2, 2015
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Luis Alejandro HERNANDEZ, Christine Margaret MUEHLENTHALER, Eric Martin VAUGHN, Gregory HAIWICK
  • Publication number: 20150056248
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of a different subtype, or the prevention or treatment of a disease caused by an infection with PCV2 of a different subtype.
    Type: Application
    Filed: August 20, 2014
    Publication date: February 26, 2015
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Gregory HAIWICK, Marc Allan EICHMEYER, Luis Alejandro HERNANDEZ, Wesley Scott JOHNSON, Christine Margaret MUEHLENTHALER, Eric Martin VAUGHN
  • Publication number: 20140322267
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype a (PCV2a) ORF2 proteins or immunogenic compositions comprising a PCV2a ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of a different subtype, or the prevention or treatment of a disease caused by an infection with PCV2 of a different subtype.
    Type: Application
    Filed: April 28, 2014
    Publication date: October 30, 2014
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Gregory HAIWICK, Luis HERNANDEZ, Wesley Scott JOHNSON, Christine Margaret MUEHLENTHALER, Eric Martin VAUGHN
  • Publication number: 20110059126
    Abstract: The present invention provides methods of reducing the vircidal activity of a composition comprising a PCV-2 antigen as well as antigenic preparations and immunogenic compositions comprising a PCV-2 antigen, wherein the virucidal activity has been reduced. In addition, the present invention also relates to a method of increasing the immunogenicity of an immunogenic composition comprising a PCV-2 antigen as well as immunogenic composition with an increased immunogenicity.
    Type: Application
    Filed: September 2, 2010
    Publication date: March 10, 2011
    Applicant: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Caroline Ann Kohler, Guosong Zhao, Ali Khazraeinazmpour, Bernd Colin Eichenmueller, Marc Allan Eichmeyer, Gregory Haiwick, Merrill Lynn Schaeffer